Disease · MONDO_0024644

myocardial ischemia

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. myocardial ischemia. Diseases, record MONDO_0024644. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0024644

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: myocardial ischemia; Open Targets
Open Targets ID: MONDO_0024644; Open Targets
Other names: IHD, ischaemic disease of myocardium, ischaemic heart disease, ischemic disease of myocardium, ischemic heart disease, myocardium ischaemic disease, myocardium ischemic disease; Open Targets
MeSH: D017202; MeSH
NCI Thesaurus: C50625; NCI Thesaurus
Highest stage of its drugs: Approval, for 3 of its 51 drugs, from PMDA; Open Targets

Drugs51

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
ASPIRIN	CHEMBL25	Small molecule	Approval	PMDA	3	2	2	Drugs and targets
CLOPIDOGREL BISULFATE	CHEMBL1083385	Small molecule	Approval	PMDA	2	1	1	Drugs and targets
PRASUGREL HYDROCHLORIDE	CHEMBL1201773	Small molecule	Approval	PMDA	1	0	0	Drugs and targets
RANOLAZINE	CHEMBL1404	Small molecule	Phase 3	ClinicalTrials.gov	4	4	4	Drugs and targets
HEPARIN	CHEMBL4650299	Oligosaccharide	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
NESIRITIDE	CHEMBL1201668	Protein	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
ABCIXIMAB	CHEMBL1201584	Antibody	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
GLUTAMINE	CHEMBL930	Small molecule	Phase 3	ClinicalTrials.gov	1	1	0	Drugs and targets
OMEGA-3 FATTY ACIDS	CHEMBL4298065		Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
ELECLAZINE	CHEMBL3707392	Small molecule	Phase 3	TTD	1	0	0	Drugs and targets

1 to 10 of 51

See all 51 drugs

Targets82

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
P2RY12	P2Y purinoceptor 12	5	Purinergic receptor P2Y12 antagonist; Purinergic receptor P2Y12 negative allosteric modulator	Approval	https://conductscience.org/library/genes/64805	Drugs and targets
SERPINC1	Antithrombin-III	4	Antithrombin-III activator	Phase 3	https://conductscience.org/library/genes/462	Drugs and targets
SLC5A2	Sodium/glucose cotransporter 2	4	Sodium/glucose cotransporter 2 inhibitor	Phase 1	https://conductscience.org/library/genes/6524	Drugs and targets
CSF3R	Granulocyte colony-stimulating factor receptor	3	Granulocyte colony stimulating factor receptor agonist	Phase 2/3	https://conductscience.org/library/genes/1441	Drugs and targets
ITGA2B	Integrin alpha-IIb/beta-3	2	Integrin alpha-IIb/beta-3 inhibitor	Phase 3	https://conductscience.org/library/genes/3674	Drugs and targets
ITGB3	Integrin alpha-IIb/beta-3	2	Integrin alpha-IIb/beta-3 inhibitor; Integrin alpha-V/beta-3 inhibitor	Phase 3	https://conductscience.org/library/genes/3690	Drugs and targets
ABCC8	Sulfonylurea receptor 1, Kir6.2	1	Sulfonylurea receptor 1, Kir6.2 blocker	Phase 1	https://conductscience.org/library/genes/6833	Drugs and targets
ADORA1	Adenosine receptor	1	Adenosine receptor agonist	Unknown	https://conductscience.org/library/genes/134	Drugs and targets
ADORA2A	Adenosine receptor	1	Adenosine receptor agonist	Unknown	https://conductscience.org/library/genes/135	Drugs and targets
ADORA2B	Adenosine receptor	1	Adenosine receptor agonist	Unknown	https://conductscience.org/library/genes/136	Drugs and targets

1 to 10 of 82

See all 82 targets

Trials29

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 5 more are not shown, since the checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT00944229	The Effect of Omega-3 Polyunsaturated Fatty Acids in Congestive Heart Failure	Phase 3	58	2016-04-22	Heart Failure	OMEGA-3 FATTY ACIDS	Its record names the disease	ClinicalTrials.gov
NCT02265796	Ranolazine Among Unrevascularized Chronic Stable Angina Patients	Phase 2	50	2017-12-04	Angina	RANOLAZINE	Its record names the disease	ClinicalTrials.gov
NCT01754259	Effects of Ranolazine on Coronary Flow Reserve in Symptomatic Diabetic Patients and CAD	Phase 3	47	2017-07-24	Diabetes, Type I, Diabetes, Type II, Angina, Coronary Artery Disease	RANOLAZINE	Its record names the disease	ClinicalTrials.gov
NCT00600106	Data Analyses for Ancillary WISE Femhrt Hormone Replacement Study	Not applicable	37	2017-12-19	Myocardial Ischemia	ETHINYL ESTRADIOL, NORETHINDRONE	Its record names the disease	ClinicalTrials.gov
NCT00570089	Microvascular Coronary Disease In Women: Impact Of Ranolazine	Phase 2	20	2015-12-03	Myocardial Ischemia	RANOLAZINE	Its record names the disease	ClinicalTrials.gov
NCT01422772	Safety Study of Gene Therapy for Ischemic Heart Disease in Korea	Phase 1/2	9	2025-10-03	Ischemic Heart Disease	DONAPERMINOGENE SELTOPLASMID	Its record names the disease	ClinicalTrials.gov
NCT02360397	Ranolazine Mediated PVC Reduction in Ischemic Heart Disease	Phase 2	6	2020-01-29	Ventricular Premature Complexes, Myocardial Ischemia	RANOLAZINE	Its record names the disease	ClinicalTrials.gov
NCT05320926	Clopidogrel Versus Aspirin MOnotherapy After 1- to 3-month of Dual-antiplatelet thErapy Following Zotarolimus-eluting Onyx Stents Implantation; C-MODE Trial	Not applicable	3,744		Ischemic Heart Disease	ASPIRIN, CLOPIDOGREL	Its record names the disease	ClinicalTrials.gov
NCT04989257	24-month Ticagrelor-based Dual-antiplatelet Therapy Versus Clopidogrel-based Dual-antiplatelet theRapy aftEr 12 Months of DrUg-eluting Stent Implantation in High isChEmic Risk Patients: P-REDUCE Trial	Not applicable	3,488		High Ischemic Risk	CLOPIDOGREL, TICAGRELOR	Its record names the disease	ClinicalTrials.gov
NCT03952273	Sort Out XI - Combo Stent Versus BioMatrix Alpha Stent	Not applicable	3,141		Coronary Artery Disease	SIROLIMUS, UMIROLIMUS	Its record names the disease	ClinicalTrials.gov

1 to 10 of 29

See all 29 trials

Comparisons in its trials7

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Ranolazine vs Sugar Pill: Ischemia Driven Revascularization or Hospitalization	3 of 25	5 of 25	50	NCT02265796	Trial comparisons
Ranolazine vs Sugar Pill: deaths from any cause	1 of 25	0 of 25	50	NCT02265796	Trial comparisons
Ranolazine vs Sugar Pill: serious adverse events	5 of 25	4 of 25	50	NCT02265796	Trial comparisons
Ranolazine vs Placebo: deaths from any cause	0 of 23	0 of 24	47	NCT01754259	Trial comparisons
Ranolazine vs Placebo: serious adverse events	0 of 23	1 of 24	47	NCT01754259	Trial comparisons
Study Drug vs Placebo: serious adverse events	0 of 20	0 of 20	40	NCT00570089	Trial comparisons
Hormone Replacement Therapy vs Placebo: serious adverse events	2 of 18	0 of 19	37	NCT00600106	Trial comparisons

Papers from its trials23

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
25925992	RESULT	1	PubMed
12117397	RESULT	1	PubMed
10636365	RESULT	1	PubMed
9672272	RESULT	1	PubMed
40406942	DERIVED	1	PubMed
39870125	DERIVED	1	PubMed
38654565	DERIVED	1	PubMed
38319239	DERIVED	1	PubMed
37987108	DERIVED	1	PubMed
37184744	DERIVED	1	PubMed

1 to 10 of 23

See all 23 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0024644

GET https://conductscience.org/api/diseases/v1/MONDO_0024644/drugs?page=2

API reference For AI assistants